Key result
Elevated levels of asymmetric dimethylarginine (ADMA) contribute to endothelial dysfunction, hypertension, and renal injury in hypertensive disorders of pregnancy.
Why the study?
Hypertensive disorders of pregnancy cause substantial maternal and neonatal morbidity and mortality, and elevated ADMA-mediated endothelial dysfunction may serve as a potential causative factor.
Answers are grounded in this paper and cite their sources.
Elevated ADMA-mediated endothelial dysfunction is proposed as a key pathophysiological mechanism and potential therapeutic target in hypertensive disorders of pregnancy.
Hypertensive disorders of pregnancy (HDP) represent a major cause of maternal and neonatal morbidity and mortality. Studies conducted over the last decade have improved our understanding of the potential mechanisms underlying HDP pathogenesis. The first step in HDP is reduced uteroplacental perfusion as a result of abnormal extravillous trophoblast invasion of spiral arterioles. Subsequent placental ischemia leads to maternal vascular endothelial dysfunction that may be caused by an imbalance between pro- and anti-angiogenic factors, enhanced formation of vasocontractile factors such as endothelin and thromboxane, increased vascular sensitivity to angiotensin II, and/or decreased formation of vasodilators such as nitric oxide (NO) and prostaglandin I2. NO is one of the major mediators from the endothelium, and its production is modified by endogenous NO synthase inhibitors such as asymmetric dimethylarginine (ADMA). ADMA levels are generally higher in patients with cardiovascular and metabolic diseases and widely recognized as a prognostic marker for major cardiovascular events and mortality. Recent studies have found ADMA levels to be higher in patients with preeclampsia. In addition, multiple studies indicate that elevated ADMA in early stages of pregnancy might predict the development of preeclampsia. Finally, ADMA has been found to be associated with uterine artery flow disturbance. Collectively, these findings strongly suggest that elevated ADMA-mediated endothelial dysfunction could be a causative factor for HDP. In this review, we discuss the biology of ADMA, with a particular focus on its potential role in HDP.
No takes yet. Share an insight, caveat, or question.
Kobayashi et al. (2020) conducted a review in Hypertensive disorders of pregnancy. Asymmetric dimethylarginine (ADMA) was evaluated. Elevated levels of asymmetric dimethylarginine (ADMA) contribute to endothelial dysfunction, hypertension, and renal injury in hypertensive disorders of pregnancy.
Synapse has enriched 10 related papers. Consider them for comparative context: